July 16, 2024

error page

Business is my step

Integra LifeSciences Completes the Sale of its Extremity Orthopedics Small business to Smith+Nephew

3 min read
Integra LifeSciences Completes the Sale of its Extremity Orthopedics Small business to Smith+Nephew
Integra LifeSciences Completes the Sale of its Extremity Orthopedics Small business to Smith+Nephew

Push release material from World Newswire. The AP news employees was not concerned in its generation.

PRINCETON, N.J., Jan. 04, 2021 (Globe NEWSWIRE) — Integra LifeSciences Holdings Company (NASDAQ:IART), a leading worldwide professional medical engineering firm, right now announced it has accomplished its beforehand declared divestiture of its Extremity Orthopedics business to Smith+Nephew (LSE:SN, NYSE:SNN).

“With this divestiture, we will now be in an even much better place to capitalize on our main goods and systems in neurosurgery and regenerative drugs, and present bigger value to our consumers and shareholders,” stated Peter Arduini, president and CEO, Integra LifeSciences. “We want to thank the orthopedics group for their contributions to Integra’s results and desire them all the greatest for their foreseeable future.”

Piper Sandler & Co. is serving as economical advisor and Morgan, Lewis & Bockius LLP is acting as authorized advisor to Integra.

About Integra LifeSciences
Integra LifeSciences is a world-wide leader in regenerative technologies and neurosurgical options committed to limiting uncertainty for clinicians, so they can focus on furnishing the very best individual care. Integra features a complete portfolio of higher quality, management makes that include things like AmnioExcel®, Bactiseal®, Certas®, Codman®, CUSA®, DuraGen®, DuraSeal®, ICP Express®, Integra®, MediHoney®, MicroFrance®, PriMatrix®, SurgiMend®, TCC-EZ®, and VersaTru®. For the most current information and information and facts about Integra and its products, you should take a look at www.integralife.com.

This news launch consists of ahead-seeking statements, such as statements about our present-day and upcoming performance inside of the that means of the Private Securities Litigation Reform Act of 1995 that entail threats and uncertainties, and mirror the Company’s judgment as of the date of this launch.  Forward-seeking statements contain, but are not restricted to, those that include terms such as “estimate,” “will,” “plan,” “should,” “expect,” “continue,” and “forecast”. Forward-on the lookout statements also include things like, but are not minimal to, statements about future monetary performance, together with projections for revenues. It is crucial to note that the Company’s plans and anticipations are not predictions of precise overall performance. This sort of ahead-wanting statements include dangers and uncertainties that could bring about actual success to vary materially from predicted or anticipated effects. This kind of challenges and uncertainties include, but are not confined to, threat variables and uncertainties identified under the heading “Risk Factors” bundled in Merchandise 1A of Integra’s Once-a-year Report on Sort 10-K for the yr finished December 31, 2019 and info contained in subsequent filings with the Securities and Exchange Commission.

These ahead-looking statements are manufactured only as of the day hereof, and the Company undertakes no obligation to update or revise the forward-seeking statements, whether or not as a end result of new data, future gatherings, or normally.

Investor Relations Make contact with
Michael Beaulieu
Director, Investor Relations
(609) 529-4812
[email protected]

Media Make contact with:
Laurene Isip
Senior Director, International Company Communications
(609) 750-7984
[email protected]

error-page.com © All rights reserved. | Newsphere by AF themes.